ArticleJournal of animal science2026
The impact of copper status on lubabegron fumarate-induced growth and adipose immune cell infiltration in beef feedlot steers.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Local insulin-like growth factor-1 and Akt/mTOR signaling in skeletal muscle of lubabegron-supplemented finishing steers.Journal of animal science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to evaluate the effect of copper (Cu) status on response to lubabegron fumarate (LUB; Experior, Elanco, Greenfield, IN) and adipose tissue physiology. Forty-eight Angus crossbred steers (469 ± 31 kg) were enrolled in a 77-day finishing study, housed in pens of six, with a GrowSafe bunk (GrowSafe Systems, Ltd, Airdrie, AB, Canada) in each pen and implanted (Revalor-200, Merck Animal Health, Madison, NJ; 200 mg TBA + 20 mg E2) on day 0. A 2 × 2 factorial arrangement was applied to Cu status (Cu0, no supplemental Cu; or Cu10, 10 mg supplemental Cu/kg DM as CuSO4) and LUB (36 mg/steer/day, LUB; or no LUB, NOLUB). A prior trial resulted in steers with distinct liver Cu (Cu0 and Cu10 were 42 ± 21 and 193 ± 31 mg Cu/kg DM, respectively). Lubabegron was fed from day 37 to day 73, and cattle harvested on day 78. Weights were collected on days -1, 0, 37, 55 (mid-Experior), 76, and 77. Blood was collected on days 0, 37, 55, and 76 for non-esterified fatty acids (NEFA), glucose, and insulin. Subcutaneous adipose biopsies were collected on days 0, 37, and 66. Data were analyzed using the MIXED procedure of SAS as a factorial design, with steer as the experimental unit (n = 12 per treatment). From days 0-37, Cu0 daily gain and feed efficiency (G: F) were greater than Cu10 (P < 0.01). Overall DMI was greater in Cu10 than Cu0 (P = 0.04) and not affected by LUB (P = 0.13). Carcass-adjusted average daily gain was greater in LUB-fed cattle (P = 0.04). During the LUB period, G: F was affected by Cu × LUB (P = 0.04), where Cu0 cattle exhibited a greater improvement in efficiency due to LUB than Cu10. The revised quantitative insulin sensitivity check index displayed a LUB × Day effect (P < 0.01) where NOLUB was consistent across days and LUB had greater insulin sensitivity during the LUB period. Populations of mononuclear phagocytes were greater in Cu0-LUB over all other treatments (LUB × Cu P = 0.02). These data suggest Cu concentration influences steer response to lubabegron fumarate, highlighting the need for further research to optimize Cu supplementation to finishing cattle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.